 Lexaria Bioscience Corp NASDAQ: LEXX said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-processed cannabidiol DehydraTECH-CBD. The study findings indicated a tendency p0.1. 